Associate Professor Anna Hearps
Co-Program Director, Disease Elimination; Head, Infection, Inflammation and Innate Immunity
Working groups
Burnet publications
View 61 moreLactic acid produced by optimal vaginal Lactobacillus spp. potently and specifically inactivates HIV-1 in vitro by targeting the viral RNA genome and reverse transcriptase
PLoS Pathogens
Muriel Aldunate et al
Afucosylated broadly neutralising antibodies targeting HIV envelope elicit enhanced NK cell-mediated cytotoxicity against HIV-infected CD4+ T cell and macrophage targets
Journal of Leukocyte Biology
Olaf G. Wilhelm et al
Adaptive NK Cells Rapidly Expand during Acute HIV Infection and Persist Despite Early Initiation of Antiretroviral Therapy
The Journal of Immunology
Anna C. Hearps et al
Reports and other work
-
Covid-19 Global Trends and Analysis - Volume 2: SARS-CoV-2 viral load dynamics and infectivity.
Covid-19 Global Trends and Analysis - Volume 2: SARS-CoV-2 viral load dynamics and infectivity.
Current projects
View 10 more
Methamphetamine and injecting drug use cohort studies: MIXMAX
MIXMAX is the largest active cohort study of people who use drugs in Australia. It combines 2 pre-existing studies: SuperMIX and VMAX.
EVE-M®: enhancing the vaginal environment and microbiome
The vaginal microbiome is a key determinant of a women’s sexual and reproductive health. There is an unmet need for effective non-antibiotic-based strategies to target bacterial vaginosis and its adverse sequelae.
Testing treatments for long COVID, a collaborative clinical trial
HEAL APT: Harnessing effective approaches for long COVID therapies through an adaptive platform trial.
